A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Clinical trial NCT04658862 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04658862
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-07
- Primary completion
- 2026-12-30
- Enrollment
- 518
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.